# A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02236611** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1036 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Umeclidinium
- **DRUG:** Glycopyrronium

## Key facts

- **NCT ID:** NCT02236611
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-26
- **Primary completion:** 2015-06-02
- **Final completion:** 2015-06-02
- **Target enrollment:** 1036 (ACTUAL)
- **Last updated:** 2018-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02236611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02236611, "A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02236611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*